CERID-led experimental medicine trial on the use of clofazimine to treat cryptosporidiosis has completed enrollment and entered the data analysis phase.
Dr. Javeed Shah and Dr. David Koelle were recently awarded NIH grants.
Join us for CERID Seminars -- the 2nd & 4th Fridays of the month
The article highlights the development of methionyl tRNA-synthetase inhibitors for the treatment of Cryptosporidiosis.
The study found that seeking care from traditional healers was a strong predictor of advanced HIV disease and that although the majority of study participants presented with advanced disease, there were numerous missed opportunities to prevent HIV-associated morbidity and mortality.
Lysyl-tRNA synthetase validated as an effective target against malaria and cryptosporidiosis.
Dr. Wes Van Voorhis, Director of CERID, recently reflected on some exciting developments within CERID.
CERID Researchers published in The Journal of Infectious Diseases: "Pharmacokinetics and In Vivo Efficacy of Pyrazolopyrimidine, Pyrrolopyrimidine, and 5-Aminopyrazole-4-Carboxamide Bumped Kinase Inhibitors against Toxoplasmosis."
Researchers explore the latest advances in Cryptosporidium research at Tufts University.
Dr. Wes Van Voorhis is conducting a Phase 2A, clinical trial on the safety, tolerability, pharmacokinetics and efficacy of clofazimine in Cryptosporidiosis.